Can Ondansetron be an Alternative to Cabergoline for Preventing Ovarian Hyperstimulation Syndrome?

dc.authorid	Kurdoglu, Mertihan/0000-0002-5344-9739
dc.contributor.author	Bakirci, Sukru
dc.contributor.author	Kurdoglu, Mertihan
dc.contributor.author	Khaki, Arash
dc.date.accessioned	2025-01-21T16:36:18Z
dc.date.available	2025-01-21T16:36:18Z
dc.date.issued	2023
dc.department	Kırıkkale Üniversitesi
dc.description.abstract	[Abstract No tAvailable]
dc.identifier.doi	10.15296/ijwhr.2023.09
dc.identifier.endpage	44
dc.identifier.issn	2330-4456
dc.identifier.issue	2
dc.identifier.scopus	2-s2.0-85153191700
dc.identifier.scopusquality	Q3
dc.identifier.startpage	44
dc.identifier.uri	https://doi.org/10.15296/ijwhr.2023.09
dc.identifier.uri	https://hdl.handle.net/20.500.12587/24292
dc.identifier.volume	11
dc.identifier.wos	WOS:000964287000001
dc.identifier.wosquality	Q4
dc.indekslendigikaynak	Web of Science
dc.indekslendigikaynak	Scopus
dc.language.iso	en
dc.publisher	Aras Part Medical Int Press
dc.relation.ispartof	International Journal of Womens Health and Reproduction Sciences
dc.relation.publicationcategory	Diğer
dc.rights	info:eu-repo/semantics/openAccess
dc.snmz	KA_20241229
dc.title	Can Ondansetron be an Alternative to Cabergoline for Preventing Ovarian Hyperstimulation Syndrome?
dc.type	Editorial

Koleksiyon